Kevin Tabury
Seminars
Tuesday 1st December 2026
From FAP to B7-H3: What Determines Whether a Radiopharmaceutical Target Successfully Translates to the Clinic?
11:30 am
- Identifying the key biological, translational and clinical characteristics that differentiate high-potential radiopharmaceutical targets from those unlikely to succeed
- Exploring how target expression, tumour microenvironment interactions and biomarker strategies influence development decisions
- Understanding the role of preclinical modelling, radiobiology and imaging in strengthening confidence before clinical translation
Tuesday 1st December 2026
Advancing Personalised Dosimetry Through LUTADose Lab: Building the Evidence Required to Optimise Radiopharmaceutical Therapy
1:30 pm
- Sharing insights from the LUTADose initiative and evaluating how personalised dosimetry approaches can improve treatment planning and patient outcomes
- Understanding how patient-specific absorbed dose measurements can be leveraged to optimise efficacy while reducing unnecessary toxicity
- Exploring the role of quantitative imaging, modelling and dosimetric assessment in moving beyond standardised dosing approaches
